Misz M, Oláh L, Kappelmayer J, Blaskó G, Udvardy M, Fekete I, Csépány T, Ajzner E, Csiba L
Debreceni Orvostudományi Egyetem Neurológiai Klinika, Klinikai Biokémiai és Molekuláris Patológiai Intézet.
Orv Hetil. 1998 Oct 18;139(42):2503-7.
The authors studied whether haemostatic abnormalities connected with the development of cerebral circulatory disturbances can be demonstrated in young stroke patients in whom Doppler and angiographic examination failed to reveal deviations indicative of stroke. They determined the in vivo activation of the coagulation system (TAT, F 1 + 2), the degree of secondary fibrinolysis (D-dimer), the plasma levels of the markers of fibrinolysis, with special regard to inhibitors: plasminogen activator inhibitor (PAI-1), alpha 2 antiplasmin (alpha 2 AP), alpha 2 macroglobulin (alpha 2 M), the frequency of pathologic serum lipoprotein (a)-Lp(a)-values and the association of PAI-1 and Lp(a) with the fibrinolytic system. They conclude that in the acute phase of the disease, the TAT and F 1 + 2 values were significantly elevated compared to the control, without change in the D-dimer value. The results suggest that in the tested period increased thrombin generation dominated and it significantly surpassed plasmin activity since the D-dimer values of that period did not indicate substantial increase in secondary fibrinolysis. The results of the study were separately analyzed in acute, chronic TIA and stroke groups. In the TIA and acute group the F 1 + 2 values, while in stroke the TAT values were more elevated. The in vitro fibrinolytic capacity of the patients significantly decreased compared to controls, showing significant correlation with the Lp(a) level, but not with the PAI value. Examination of the marker molecules renders possible to assess the degree of hypercoaguability and of endogenous lysis. Their knowledge is held important for judging the progression of the disease and the therapeutic consequences.
作者研究了在经多普勒和血管造影检查未发现提示中风的异常情况的年轻中风患者中,是否能证实存在与脑循环障碍发展相关的止血异常。他们测定了凝血系统的体内激活情况(凝血酶 - 抗凝血酶复合物、纤维蛋白肽A)、继发性纤溶程度(D - 二聚体)、纤溶标志物的血浆水平,特别关注抑制剂:纤溶酶原激活物抑制剂(PAI - 1)、α2抗纤溶酶(α2AP)、α2巨球蛋白(α2M)、病理性血清脂蛋白(a)-Lp(a)值的频率以及PAI - 1和Lp(a)与纤溶系统的关联。他们得出结论,在疾病急性期,与对照组相比,凝血酶 - 抗凝血酶复合物和纤维蛋白肽A值显著升高,而D - 二聚体值无变化。结果表明,在测试期间,凝血酶生成增加占主导,且显著超过纤溶酶活性,因为该时期的D - 二聚体值未表明继发性纤溶有实质性增加。研究结果分别在急性、慢性短暂性脑缺血发作(TIA)和中风组中进行了分析。在TIA和急性组中纤维蛋白肽A值升高,而在中风组中凝血酶 - 抗凝血酶复合物值升高更明显。与对照组相比,患者的体外纤溶能力显著降低,与Lp(a)水平显著相关,但与PAI值无关。对标志物分子的检测使得评估高凝程度和内源性纤溶程度成为可能。它们的信息对于判断疾病进展和治疗效果具有重要意义。